You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Tryptophan, adenosine, neurodegeneration and neuroprotection
|
|---|---|
| Published in |
Metabolic Brain Disease, August 2007
|
| DOI | 10.1007/s11011-007-9064-3 |
| Pubmed ID | |
| Authors |
T. W. Stone, C. M. Forrest, G. M. Mackay, N. Stoy, L. G. Darlington |
| Abstract |
This review summarises the potential contributions of two groups of compounds to cerebral dysfunction and damage in metabolic disease. The kynurenines are oxidised metabolites of tryptophan, the kynurenine pathway being the major route for tryptophan catabolism in most tissues. The pathway includes quinolinic acid -- an agonist at N-methyl-D-aspartate (NMDA) receptors, kynurenic acid -- an antagonist at glutamate and nicotinic receptors, and other redox active compounds that are able to generate free radicals under many physiological and pathological conditions. The pathway is activated in immune-competent cells, including glia in the central nervous system, and may contribute substantially to delayed neuronal damage following an infarct or metabolic insult. Adenosine is an ubiquitous purine that can protect neurons by suppressing excitatory neurotransmitter release, reducing calcium fluxes and inhibiting NMDA receptors. The extent of brain injury is critically dependent on the balance between the two opposing forces of kynurenines and purines. |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 41 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 23% |
| Student > Bachelor | 7 | 16% |
| Student > Ph. D. Student | 6 | 14% |
| Student > Master | 4 | 9% |
| Student > Postgraduate | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 9 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 9 | 21% |
| Medicine and Dentistry | 7 | 16% |
| Nursing and Health Professions | 3 | 7% |
| Psychology | 3 | 7% |
| Chemistry | 3 | 7% |
| Other | 7 | 16% |
| Unknown | 11 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2023.
All research outputs
#7,730,464
of 23,510,717 outputs
Outputs from Metabolic Brain Disease
#356
of 1,083 outputs
Outputs of similar age
#24,980
of 68,800 outputs
Outputs of similar age from Metabolic Brain Disease
#1
of 5 outputs
Altmetric has tracked 23,510,717 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 68,800 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them